Medically authored by Dr. Mario Quiros, MD — Board-Certified Emergency Medicine & Obesity Medicine Physician | Good Hearts Health

Retatrutide — nicknamed “triple G” or “GGG” in fitness communities — has become one of the most talked-about compounds in gym culture. Unlike semaglutide or tirzepatide, which carry FDA approval and physician oversight, retatrutide is not yet approved for human use. That hasn’t stopped it from flooding online peptide markets and underground supplement forums — and it hasn’t stopped men at gyms from injecting it.

As a physician who specializes in GLP-1 therapy and obesity medicine, what I’m seeing in this space concerns me deeply.

Why Retatrutide Has Exploded in Gym Culture

Retatrutide is a triple receptor agonist — it simultaneously activates the GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, the TRIUMPH-1 Phase 3 trial reported in May 2026 showed participants on the 12 mg dose lost an average of 70.3 lbs (28.3%) of body weight over 80 weeks — results unprecedented in the weight loss space.

What caught the attention of the bodybuilding and fitness community specifically was the glucagon component. Glucagon is a hormone associated with fat mobilization and energy expenditure, and the narrative that spread rapidly through fitness forums, YouTube channels, and private Discord groups became: “Retatrutide doesn’t just make you lose weight — it makes you lose fat while keeping your muscle.”

That narrative is, at best, misleading. At worst, it is dangerous.

The Stack: What Men in Gyms Are Combining with Retatrutide

The use of retatrutide in gym culture rarely happens in isolation. It is being used as part of what fitness communities call a “recomp stack” — compounds combined with the goal of simultaneously losing fat and preserving muscle. Common compounds being used alongside retatrutide include:

Anabolic Steroids

• Testosterone (various esters) — by far the most common co-administration. Testosterone directly stimulates muscle protein synthesis and counteracts the caloric deficit-driven muscle loss associated with GLP-1 therapy.
• Nandrolone (Deca-Durabolin) — favored for its joint-protective properties and muscle-preserving effects during aggressive cutting phases.
• Primobolan (Methenolone) — popular for lean muscle retention without significant water retention.
• Trenbolone — used by more advanced users for its potent fat-burning and muscle-hardening effects, though it carries significant cardiovascular and psychiatric risk.

SARMs (Selective Androgen Receptor Modulators)

• RAD-140 (Testolone) — marketed as a “safer” testosterone alternative for muscle preservation.
• LGD-4033 (Ligandrol) — used primarily for lean mass retention during caloric restriction.
• Ostarine (MK-2866) — widely promoted in fitness communities as muscle-sparing with minimal androgenic side effects.

Peptides and Growth Hormone Secretagogues

• Ipamorelin / CJC-1295 — growth hormone-releasing peptides used to boost HGH levels, muscle recovery, and fat metabolism.
• MK-677 (Ibutamoren) — an oral growth hormone secretagogue promoted for muscle gain and improved body composition.
• BPC-157 and TB-500 — promoted for recovery and tissue repair. As I have written about previously in my guide on peptide safety, both are FDA-banned for human use and lack long term safety and efficacy data.  

Multi-GLP-1 Stacking

Some users are stacking retatrutide with tirzepatide or semaglutide in an attempt to create a more aggressive weight loss effect — a practice that carries significant risks including severe gastrointestinal complications, pancreatitis, and thyroid C-cell stimulation.

Why People Think Retatrutide Is Muscle-Sparing — And Why They’re Wrong

This is where the science matters most, and where gym culture’s anecdotal reporting is leading people astray. Phase 2 body composition data published in The Lancet Diabetes & Endocrinology showed that at the 12 mg dose over 48 weeks, approximately 74–75% of weight lost was fat mass, with 25–26% attributable to lean mass reduction. That lean mass figure is broadly comparable to other GLP-1 agents — there is no clinically validated evidence that retatrutide is uniquely muscle-sparing.

1. Confusing the Glucagon Effect with Muscle Protection

Yes, glucagon promotes fat oxidation. But glucagon is also catabolic — it can promote gluconeogenesis, the conversion of amino acids from muscle protein into glucose for energy. There is no reliable clinical evidence that retatrutide’s glucagon component selectively spares lean mass at the doses circulating in underground markets.

2. The Anabolics Are Doing the Work — Not Retatrutide

When someone stacks retatrutide with testosterone and reports “zero muscle loss,” the testosterone is almost certainly responsible for the muscle preservation. Exogenous testosterone dramatically increases muscle protein synthesis even in a significant caloric deficit. Attributing muscle-sparing to retatrutide in this context is a fundamental confounding variable error — and it spreads unchecked in communities where no physician oversight exists.

3. Short-Term Use Masks Long-Term Risk

Most users reporting favorable results are within the first 8 to 16 weeks of use. GLP-1-driven muscle loss tends to accelerate over time as the rate of weight loss outpaces the body’s ability to preserve lean tissue — particularly without adequate protein intake and structured resistance training.

4. Underground Market Doses Are Not Clinical Doses

The doses circulating in underground markets are often far higher or far lower than those studied in Phase 2 trials — with no quality assurance, sterility testing, or dosing accuracy. Exposures tracked by America’s Poison Centers surged to approximately 95 reports per month in early 2026, a 265% increase from the prior period.

5. Survivorship Bias in Online Reporting

The people posting physique updates and body recomposition success stories are, by definition, the ones who had positive experiences. The adverse events — significant muscle loss, cardiac arrhythmias, pancreatitis, severe nausea and malnutrition, severe hypoglycemia — do not get the same visibility on Instagram or fitness forums.

Why the Unregulated Status Is Fueling the Fire

Retatrutide is classified as a research chemical. It is not approved by the FDA for human use. It cannot be legally prescribed by a physician. The FDA issued warning letters to multiple websites in September 2025 for selling compounded or counterfeit retatrutide in violation of federal law. And yet it continues to be sold openly, often sourced from unregulated manufacturers — with no quality control on purity, potency, or sterility.

Several factors make the unregulated status a direct accelerant to its popularity in fitness culture:

• No prescription required. For gym communities already accustomed to purchasing SARMs and peptides through gray market channels, buying retatrutide online requires nothing more than a credit card and clicking a box stating it is “for research purposes only.”
• No physician oversight means no accountability. No one is monitoring cardiac function, thyroid markers, liver enzymes, or lean body mass. No one is adjusting the dose based on response. And critically, there is no one to call when something goes wrong.
• Significantly cheaper than FDA-approved GLP-1 therapy. Branded tirzepatide can cost several hundred dollars per month. Underground retatrutide is obtained at a fraction of that cost — with zero pharmaceutical-grade quality assurance.
• Exclusivity is reframed as desirability. In fitness culture, access to hard-to-obtain compounds carries social currency. The fact that retatrutide isn’t available at a pharmacy is reframed as a feature — “ahead of the curve,” “what the pros are using.” This makes the lack of FDA approval sound like an advantage rather than a serious safety signal.
• Regulatory lag on athletic prohibitions. While GLP-1 receptor agonists face increasing scrutiny in competitive sports, retatrutide’s specific inclusion on prohibited substance lists has not kept pace with its real-world use in athletic populations.

Dr. Q’s Take

Retatrutide may very well become a significant advance in obesity medicine once FDA review is complete. The Phase 3 trial data is genuinely promising. But the gym community’s adoption of an unapproved, unregulated compound — injected at self-determined doses, stacked with anabolic steroids and banned peptides — is not a preview of the future of weight loss medicine. It is an experiment being conducted on people who do not fully understand the risks they are taking.

The best results I see in my practice come from patients who are supervised, monitored, dosed appropriately, and supported throughout their weight loss journey. No online forum, peptide vendor, or fitness influencer can offer that.

Ready to Start a Safe, Physician-Supervised GLP-1 Weight Loss Program?

At Good Hearts Health, Dr. Mario Quiros provides personalized, board-certified concierge weight loss care using FDA-approved Semaglutide and Tirzepatide therapy. If you are considering GLP-1 therapy for weight loss, we offer a free initial consultation to see if our program is right for you.

Book your free consultation with Good Hearts Health today →

If you are experiencing any unexpected skin reactions, allergic responses, or side effects while using any GLP-1-class compound — whether FDA-approved or not — please consult a physician immediately.

References & Further Reading

• Eli Lilly TRIUMPH-1 Phase 3 Results: Retatrutide Delivered 28.3% Weight Loss Over 80 Weeks (May 2026)
• Eli Lilly TRIUMPH-4 Phase 3 Results: Retatrutide & Osteoarthritis (December 2025)
• Eli Lilly: What to Know About Retatrutide
• BioPharma Dive: Lilly’s Triple-Acting Obesity Drug Hits Goal in Phase 3 Trial
• The Lancet Diabetes & Endocrinology: Effects of Retatrutide on Body Composition — Phase 2 Substudy
• Cell Reports Medicine: GLP-1 Medicines Do Not Result in Disproportionate Muscle Mass Loss
• CBS News: This Weight-Loss Drug Hasn’t Been Approved by the FDA. Doctors Are Prescribing It Anyway.
• WUSF: People Are Buying Unregulated Injectable Peptides from Chinese Factories. Are They Safe?
• Drugs.com: What Is “Retatrutide Peptide” Being Sold Online?
• ClinicalTrials.gov: TRIUMPH Phase 3 Study of Retatrutide in Obesity/Overweight

Medically Authored by Dr. Mario Quiros, MD. Board-Certified Emergency Medicine and Obesity Medicine Physician. Owner and Operator of Good Hearts Health.

Retatrutide is the most powerful weight-loss drug ever tested — and it is not FDA-approved. Before you consider sourcing it from the grey market, read this physician-authored breakdown of its risks, how it differs from semaglutide and tirzepatide, and why the rebound weight gain may be worse than any medication currently on the market.

Medically authored by Dr. Mario Quiros, MD — Board-Certified Emergency Medicine & Obesity Medicine Physician | Good Hearts Health

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed the treatment of type 2 diabetes and obesity. But as millions of patients now use these medications, reports of skin hypersensitivity reactions are drawing increased attention from clinicians and patients alike.

If you are experiencing a rash, hives, or injection site irritation while on a GLP-1 medication, this guide covers everything you need to know.

What Are Skin Hypersensitivity Reactions?

Skin hypersensitivity reactions are immune-mediated responses in which the body overreacts to a substance — in this case, a GLP-1 receptor agonist or one of its inactive ingredients. These reactions range from mild localized irritation to rare but serious systemic allergic responses.

They are distinct from simple side effects like nausea or diarrhea. Skin reactions involve the immune system and can evolve unpredictably, which is why early recognition matters.

What Causes Skin Hypersensitivity Reactions in GLP-1 Medications?

Several mechanisms can trigger skin reactions in patients taking GLP-1 medications:

1. Injection Site Reactions

The most common skin reaction, affecting an estimated 5–20% of patients. Localized redness, swelling, itching, bruising, or nodule formation at the injection site can result from the needle puncturing subcutaneous tissue repeatedly in the same location, the pH or osmolality of the drug formulation irritating local tissue, or a localized immune response to the peptide or excipients.

2. IgE-Mediated (Type I) Hypersensitivity

This is a true allergic reaction where the immune system produces IgE antibodies against the drug or its components. It can manifest as urticaria (hives), angioedema (swelling of deeper tissue layers), or — in rare cases — anaphylaxis. Symptoms typically occur within minutes to hours of administration.

3. Delayed (Type IV) Hypersensitivity

A T-cell-mediated reaction that develops 24–72 hours after exposure. This typically presents as a contact-dermatitis-like rash at or around the injection site and may worsen with repeated exposure.

4. Bullous Pemphigoid

A rare but serious skin condition linked to certain GLP-1 agents. It causes large, fluid-filled blisters on the skin due to autoantibodies attacking the skin’s basement membrane. The exact mechanism is still under investigation, but immunomodulatory effects of the drug class are suspected.

5. Lipodystrophy

Repeated injections in the same site can cause lipoatrophy (loss of fat) or lipohypertrophy (excess fat buildup), altering skin texture and drug absorption. While not a traditional allergic reaction, it reflects a localized tissue response to repetitive mechanical and chemical injury.

How Common Are These Reactions?

Injection site reactions (mild) occur in an estimated 5–20% of patients. Urticaria or generalized rash affects 1–5%. Angioedema occurs in under 1%. Bullous pemphigoid is rare, based on case reports and emerging data. Anaphylaxis is very rare (under 0.1%), and DRESS is very rare as well.

Mild injection site reactions are by far the most common and typically resolve on their own. Serious systemic reactions are uncommon but require immediate medical attention.

Are GLP-1 Skin Reactions Dangerous?

Most are not. The majority of patients who experience skin reactions have mild, localized symptoms that improve without medical intervention or with simple management strategies.

However, certain reactions warrant urgent care. Seek emergency care immediately if you notice: throat tightening, difficulty breathing, or wheezing (signs of anaphylaxis); rapid spread of hives across the body combined with dizziness or a drop in blood pressure; widespread blistering of the skin; or fever, facial swelling, or internal organ symptoms alongside a rash (possible DRESS).

Bullous pemphigoid, while not immediately life-threatening, can be debilitating and requires prompt dermatological evaluation. If left untreated, blistering can lead to secondary infections and significant morbidity — particularly in older adults.

How Are GLP-1 Skin Hypersensitivity Reactions Treated?

Mild Injection Site Reactions

Rotate injection sites (abdomen, thigh, upper arm) with each dose. Apply a cool compress after injecting. Use over-the-counter topical hydrocortisone cream to reduce localized inflammation. Oral antihistamines (e.g., cetirizine, loratadine) can relieve itching.

Urticaria and Generalized Rash

Oral antihistamines are first-line treatment. If symptoms persist, a short course of oral corticosteroids may be prescribed. Depending on severity, the prescribing clinician may pause or switch the GLP-1 medication.

Angioedema

Mild angioedema without airway involvement: antihistamines and monitoring. Severe angioedema or any airway compromise: epinephrine (EpiPen), emergency care, and discontinuation of the drug.

Anaphylaxis

Immediate epinephrine injection (IM, lateral thigh), emergency transport, permanent discontinuation of the offending GLP-1 agent, and allergy/immunology evaluation for potential cross-reactivity with other agents in the class.

Bullous Pemphigoid

Dermatology referral is essential. Topical or systemic corticosteroids are the cornerstone of treatment. Immunosuppressants (e.g., dapsone, azathioprine, methotrexate) may be used in refractory cases. The GLP-1 medication is typically discontinued, though the decision should be weighed against the patient’s metabolic needs.

How to Prevent Skin Hypersensitivity Reactions on GLP-1 Medications

Before Starting Treatment

• Disclose your full allergy history to your prescribing clinician, including reactions to other injectable medications or peptide-based drugs.
• Review excipient ingredients in the specific formulation — some patients react to inactive ingredients like polysorbate 80 or metacresol rather than the active peptide itself.
• Start with a supervised first injection if there is any concern about hypersensitivity history.

Injection Technique

• Rotate sites systematically — never inject the same spot twice in a row; use a rotation chart if needed.
• Allow the pen or syringe to reach room temperature before injecting (10–15 minutes out of the refrigerator) to reduce local irritation.
• Pinch the skin gently and inject at the correct angle to ensure subcutaneous — not intramuscular — delivery.
• Do not inject into areas of active irritation, redness, bruising, or lipodystrophy.

Ongoing Monitoring

• Inspect injection sites after every dose for early signs of reaction.
• Keep a symptom log for the first 8–12 weeks of treatment, noting any skin changes, their timing relative to injections, and their location.
• Communicate promptly with your healthcare provider about any new or worsening skin symptoms — do not wait until the next scheduled appointment.

For Patients with a Previous Mild Reaction

• A clinician may recommend premedication with an antihistamine 30–60 minutes before each injection.
• Switching to a different GLP-1 agent with a different formulation may eliminate the reaction if the trigger is an excipient rather than the peptide class itself.
• Desensitization protocols are experimental and not standard of care, but may be considered in specialist settings for patients with significant metabolic benefit from the drug.

When Should You Stop Taking a GLP-1 Medication?

Stop the medication and contact your provider if you experience a rash that is rapidly spreading, blistering, or involving mucous membranes; any symptoms of anaphylaxis (airway involvement, hypotension, loss of consciousness); widespread blistering suggestive of bullous pemphigoid; or a rash accompanied by fever, facial swelling, or lymph node enlargement.

For mild injection site reactions alone, you do not need to stop the medication — site rotation and topical care are usually sufficient. Injection site reactions often resolve on their own a few weeks after they initially appear.  I typically do not recommend discontinuing the medication for mild, localized injection site reactions unless they are causing a patient distress due to persistent itching or irritation.  Any side effects should be reported to the physician prescribing you the medication and decisions to discontinue medication should only be made after notifying your physician. 

The Bottom Line

Skin hypersensitivity reactions to GLP-1 medications are real but, in the vast majority of cases, manageable. Mild injection site reactions are common and rarely require stopping treatment. Serious systemic reactions — while medically significant — are uncommon.

The key is awareness: patients and clinicians who know what to watch for can catch reactions early, respond appropriately, and make informed decisions about whether to continue, modify, or discontinue treatment. Given the substantial cardiometabolic benefits of GLP-1 medications, the goal is always to keep patients on therapy safely whenever possible.

Frequently Asked Questions

Q: Can I switch to a different GLP-1 medication if I have a skin reaction?
Yes, in many cases. If the reaction is caused by an excipient rather than the GLP-1 peptide itself, switching formulations may resolve it. However, if the reaction is to the peptide class broadly, cross-reactivity is possible. An allergist can help assess this.

Q: Do you see a higher incidence of Skin Reactions with Tirzepatide compared to Semaglutide?
Yes, localized skin reactions are much more common with Tirzepatide compared to Semaglutide.  While Tirzepatide is a more effective drug in terms of weight loss and generally has a more favorable side effect profile, I do see an increased incidence of localized skin reactions in patients taking Tirzepatide compared to patients taking Semaglutide. 

Q: How long do injection site reactions typically last?
Most resolve within a few hours to days. If a reaction persists beyond a week or worsens, contact your provider.

Q: Can GLP-1 medications cause eczema to flare?
There is limited evidence that GLP-1 agents directly trigger eczema flares, but the immune modulation and skin barrier disruption at injection sites may worsen pre-existing atopic conditions in some patients.

Q: Is bullous pemphigoid permanent?
Not always. In drug-induced cases, discontinuing the offending medication often leads to remission, though treatment is still required while the blistering is active.

Q: Should I carry an EpiPen if I’m on a GLP-1 medication?
Not routinely. Your clinician will advise you on whether your personal risk profile warrants a prescribed epinephrine auto-injector.

Q: Where can I book a consultation with a board certified Obesity Medicine physician and see if GLP-1 therapy for weight loss may be right for me?
You can visit our website and book a free consultation to see if our concierge weight loss program is right for you. 

References & Further Reading

• FDA Prescribing Information: Ozempic (Semaglutide) — Hypersensitivity & Adverse Reactions
• Burke et al. (2025). Dermatologic Implications of GLP-1 Receptor Agonist Medications. Skin Appendage Disorders. Karger Publishers.
• Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons. PMC/NIH.
• Tirzepatide in Dermatology: Cutaneous Adverse Events, Emerging Therapeutic Roles, and Cosmetic Implications — A Comprehensive Review. PMC/NIH.
• Semaglutide-Associated Bullous Pemphigoid. PMC/NIH.
• Examining the Association of GLP1-RA or DPP4i with Bullous Skin Diseases in Veterans. Journal of the Endocrine Society. Oxford Academic.
• Identifying Potential Drug Triggers for Bullous Pemphigoid: A Disproportionality Analysis of the FDA Adverse Event Reporting System. Cutaneous and Ocular Toxicology.
• Desensitization to Tirzepatide After Recurrent Maculopapular Eruptions to GLP-1 Agonists. Annals of Allergy, Asthma & Immunology.
• A Case Report of Systemic Allergic Reaction to the Dual GIP/GLP-1 Receptor Agonist Tirzepatide. PMC/NIH.
• Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. American Journal of Case Reports.
• GLP-1 Agonists Associated With Rare Cutaneous Adverse Reactions. Dermatology Advisor.

Ready to Start a Physician-Supervised GLP-1 Weight Loss Program?

At Good Hearts Health, Dr. Mario Quiros provides personalized, board-certified concierge weight loss care using FDA-approved Semaglutide and Tirzepatide therapy. If you are considering GLP-1 therapy and want to do so safely — with proper medical oversight and monitoring for reactions like those described above — we are here to help.

Book your free consultation with Good Hearts Health today →

Medically Authored by Dr. Mario Quiros, MD. Board-Certified Emergency Medicine and Obesity Medicine Physician. Owner and Operator of Good Hearts Health.

Article Summary:

The FDA has officially declared the end of the tirzepatide shortage and semaglutide shortage, meaning that brand-name medications like Mounjaro®/Zepbound® (tirzepatide) and Ozempic®/Wegovy® (semaglutide) are now widely available. This decision impacts compounding pharmacies and outsourcing facilities, which were previously allowed to produce copies of these medications under emergency provisions.

How Compounding Pharmacies Continue to Serve Patients with Unique Needs:

The FDA recently declared the shortages of tirzepatide and semaglutide officially resolved, marking a turning point in the availability of these widely used medications for weight management and type 2 diabetes. While this announcement ensures that FDA-approved products like Mounjaro^®/Zepbound^® (tirzepatide) and Ozempic^®/Wegovy^® (semaglutide) are now readily accessible, it also signals a shift in the role of compounding pharmacies and outsourcing facilities. The physicians and pharmacies, which played a critical role during the shortages, are now adapting to continue serving patients with unique healthcare needs through clinically differentiated formulations.

The FDA’s Decision and Its Implications:

The semaglutide and tirzepatide shortages, which began in 2022 due to high demand, initially allowed compounding pharmacies and outsourcing facilities to produce copies of these medications under provisions of Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. ⁴

However, the FDA has determined that by December 2024 for tirzepatide and February 2025 for semaglutide, manufacturers will be able to meet national demand, leading to the removal of these drugs from the shortage list.

As a result, compounding pharmacies and outsourcing facilities will no longer be able to produce copies of these drugs under the emergency provisions.^1, 2, 3

Specifically:

• Compounding pharmacies will no longer be able to make copies of semaglutide after April 22, 2025, and tirzepatide after March 19, 2025, unless they can demonstrate a documented clinical difference that addresses specific patient needs, in accordance with Section 503A of the Federal Food, Drug, and Cosmetic Act.
• Outsourcing facilities will no longer be able to produce semaglutide after May 22, 2025, and tirzepatide after March 19, 2025.

This regulatory shift means that outsourcing facilities can no longer produce these drugs in any form and compounding pharmacies can no longer produce copies of these drugs unless they provide a documented clinical difference that meets specific patient needs under Section 503A of the Federal Food, Drug, and Cosmetic Act.⁴

Role of Compounding Pharmacies Post-Shortage: 

Even as enforcement tightens, compounding pharmacies remain essential for patients who require customized versions of tirzepatide or semaglutide. Here’s how they continue to make a difference:

Differences in Formulations: 

Compounding pharmacies can continue to legally produce tirzepatide or semaglutide with modifications that address unique patient needs. For example:

• Adding Active Pharmaceutical Ingredients: Some compounded formulations include niacinamide (a form of vitamin B3), which may offer additional metabolic benefits.

Orally Disintegrating Tablets (ODTs): For patients who struggle with injections or have needle phobia, ODTs may provide a convenient alternative delivery method.^4, 8

These modifications are not available in FDA-approved GLP-1 products but may improve treatment adherence and outcomes for certain patients.

Personalized Dosages:

While many commercial products are available in fixed doses, compounded medications can be tailored to provide precise dosages that align with individual medical requirements.

This flexibility is particularly valuable for patients who experience side effects at standard doses or require gradual titration.

To learn more about customized medication dosing book your free consult at:

WWW.GOODHEARTSHEALTH.COM

Challenges Ahead:

Despite their critical role during shortages, compounding pharmacies face increasing scrutiny from regulatory agencies. Both Eli Lilly (maker of Mounjaro®/Zepbound®) and Novo Nordisk (maker of Ozempic®/Wegovy®) have raised concerns about counterfeit or substandard compounded versions of their drugs.^1, 8

To address these concerns, compounding pharmacies must continue to prioritize transparency and adherence to legal requirements.

Conclusion:

The resolution of the tirzepatide and semaglutide shortages marks a new chapter in patient care. While FDA-approved products are now widely available, compounding pharmacies remain indispensable for those who require personalized formulations. By offering options like niacinamide-enhanced injections or orally disintegrating tablets, these pharmacies may help ensure that personalized care remains accessible to all patients. As the healthcare landscape evolves, compounding pharmacies will continue to adapt, demonstrating their commitment to meeting unique patient needs while adhering to high standards of safety and quality.

References:

1. https://www.healio.com/news/endocrinology/20241220/fda-confirms-end-of-tirzepatide-shortage

2. https://www.bipc.com/fdas-removal-of-semaglutide-and-the-evolving-tirzepatide-decisions-what-compounders-need-to-know

3. https://www.healio.com/news/endocrinology/20250221/fda-removes-semaglutide-from-drug-shortage-list

4. https://www.techtarget.com/pharmalifesciences/feature/Understanding-tirzepatide-compounding-restrictions

5. https://time.com/6301552/weight-loss-drugs-compounding-pharmacies/

6. https://ncpa.org/newsroom/qam/2025/03/13/fda-ends-compounding-discretion-tirzepatide-maintains-discretion

7. https://www.mwe.com/insights/semaglutide-shortage-resolved/

8. https://www.medpagetoday.com/special-reports/exclusives/111577

9. https://www.yahoo.com/lifestyle/millions-of-people-are-taking-compounded-weight-loss-drugs-now-theyre-about-to-disappear-202621562.html

10. https://www.blogs.joinmochi.com/blogs/tirzepatide-vs-semaglutide

11. https://qz.com/ozempic-glp1-shortage-compounded-tirzepatide-1851769293

12. https://www.fiercepharma.com/pharma/compounders-sue-fda-again-over-declaring-end-shortage-novos-semaglutide

13. https://abcnews.go.com/GMA/Wellness/compound-versions-weight-loss-drugs-longer-fda-rules/story?id=119665010

14. https://www.drugs.com/medical-answers/you-tirzepatide-compounding-pharmacy-3575862/

15. https://newdrugloft.com/tirzepatide-injections-an-alternative-to-compounded-semaglutide/

16. https://www.cbsnews.com/news/fda-declares-end-to-wegovy-and-ozempic-shortage/

17. https://www.pharmacytimes.com/view/fda-ends-semaglutide-shortage-listing-contributing-to-ongoing-legal-challenges

18. https://sesamecare.com/blog/semaglutide-shortage

Ready to Start a Physician-Supervised GLP-1 Weight Loss Program?

At Good Hearts Health, Dr. Mario Quiros provides personalized, board-certified concierge weight loss care using FDA-approved Semaglutide and Tirzepatide therapy. If you are considering GLP-1 therapy for weight loss, we offer a free initial consultation to see if our program is right for you.

Book your free consultation with Good Hearts Health today →

Medically authored by Dr. Mario Quiros, MD — Diplomate of the American Board of Obesity Medicine | Good Hearts Health | Last medically reviewed: June 2026

“How many milligrams do I take?” and “How do I measure that in units on a syringe?” — these are questions I answer every single day in my weight loss practice. If you’re taking compounded semaglutide or tirzepatide for weight loss, understanding your exact dose is critical for both safety and results.

This complete semaglutide and tirzepatide dosing guide covers everything: how doses are measured in milligrams, how to convert mg to mL, and exactly how many units to draw on an insulin syringe — including the specific dosing schedules we use at Good Hearts Health.

What Are Semaglutide and Tirzepatide?

Semaglutide and tirzepatide are GLP-1 receptor agonists (tirzepatide also targets GIP receptors) approved for weight management and type 2 diabetes. Compounded versions of both medications are prescribed by weight loss physicians and dosed via weekly subcutaneous injection using a standard U-100 insulin syringe.

What Is Your Semaglutide or Tirzepatide Dose in Milligrams?

Both Semaglutide and Tirzepatide are dosed in milligrams (mg). You should always start on the lowest dose and titrate upward based on three key factors:

1. How Long Have You Been at Your Current Dose?

It is recommended that you stay at each dose for a minimum of 4 weeks before increasing. This allows your body to acclimate to the medication and prevents side effects that can occur from increasing the dose too quickly.

2. Are You Experiencing Side Effects?

If you are having side effects at your current dose, do not increase your dosage until those side effects have resolved. Increasing too soon will likely make them worse.

3. Are You Losing Weight?

I recommend a consistent weight loss of 1.5 to 2 lbs per week as a target. If you are hitting this consistently, there is no need to increase your dose. I only recommend a dosage increase if weight loss falls below this threshold or you hit a plateau.

How to Convert Your Semaglutide or Tirzepatide Dose from mg to Units

Every compounded medication has a concentration expressed in mg/mL — meaning how many milligrams of the drug are dissolved in 1 mL of liquid. Every 1 mL equals 100 units on an insulin syringe.

Once you know your concentration and your desired dose in mg, you can calculate exactly how many units to draw up.

The Formula: mg to mL

Desired dose (mg) ÷ Concentration (mg/mL) = Volume to inject (mL)

Example — Semaglutide starting dose:
0.25 mg ÷ 5 mg/mL = 0.05 mL

Converting mL to Units on a Syringe

To convert mL to units, multiply by 100:

0.05 mL × 100 = 5 units

So a 0.25 mg dose of Semaglutide (5 mg/mL concentration) = 5 units on an insulin syringe.

How to Calculate Your Dose in mg If You Only Know Your Units

This is one of the most common questions I get from patients who are new to my practice or transferring from another provider. Many patients are told how many units to inject but don’t know what that equals in milligrams.

The Formula: Units to mg

(Units ÷ 100) × Concentration (mg/mL) = Dose in mg

Example — Tirzepatide patient taking 44 units at 17 mg/mL:
(44 ÷ 100) × 17 mg/mL = 7.5 mg

So 44 units of Tirzepatide at 17 mg/mL = 7.5 mg of the medication.

Good Hearts Health Dosing Schedules

The following are the dosing guidelines I use for patients at Good Hearts Health, based on the specific concentrations of Semaglutide and Tirzepatide we currently prescribe.

Starting dose for Semaglutide: 0.25 mg weekly = 5 units (0.05 mL) on the insulin syringe provided.
Starting dose for Tirzepatide: 2.5 mg weekly = 15 units (0.15 mL) on the insulin syringe provided.

Semaglutide Dosing Schedule (5 mg/mL Concentration)

Tirzepatide Dosing Schedule (17 mg/mL Concentration)

Important reminder: The goal is always the lowest effective dose. If you are tolerating the medication well and losing 1.5–2 lbs per week consistently, there is no reason to increase your dose. Only consider increasing after 4 weeks at your current dose if weight loss has plateaued.

Frequently Asked Questions About Semaglutide and Tirzepatide Dosing

Q: How do I know if my Semaglutide dose is working?
A consistent weight loss of 1.5–2 lbs per week indicates your dose is effective. If you are losing weight steadily, stay at your current dose — more is not always better.

Q: What happens if I increase my dose too quickly?
Increasing your dose before your body has acclimated increases the risk of side effects including nausea, vomiting, and GI discomfort. Always stay at each dose for at least 4 weeks.

Q: Can I calculate my Tirzepatide dose in units at home?
Yes. Use this formula: (Units ÷ 100) × Concentration (mg/mL) = Dose in mg. You will need to know the concentration of your specific medication vial.

Q: What concentration of Semaglutide does Good Hearts Health prescribe?
Good Hearts Health prescribes Semaglutide at 5 mg/mL and Tirzepatide at 17 mg/mL. If you are using medication from a different provider, confirm your concentration before calculating your dose.

Q: Is Tirzepatide dosed differently than Semaglutide?
Yes. While both medications are dosed in mg, Tirzepatide has a different concentration and dosing schedule. Always follow the schedule specific to your medication and concentration.

Q: How many units is 0.25 mg of semaglutide?
At a concentration of 5 mg/mL (the concentration used at Good Hearts Health), 0.25 mg of semaglutide equals 5 units on an insulin syringe. If your vial has a different concentration, divide 0.25 by your concentration and multiply by 100.

Q: How many units is 2.5 mg of tirzepatide?
At a concentration of 17 mg/mL (the concentration used at Good Hearts Health), 2.5 mg of tirzepatide equals approximately 15 units. Concentrations vary by pharmacy — always verify your specific vial.

Q: What syringe should I use for compounded semaglutide or tirzepatide?
Use a standard U-100 insulin syringe. Every 1 mL on a U-100 syringe equals 100 units, which is the basis for all unit calculations in this guide.

Final Thoughts from Dr. Q

One of my mentors used to tell me, “Life is complicated, but medicine makes sense!” I hope this guide on Semaglutide and Tirzepatide dosing has made things a little clearer. Understanding your dose — in mg, mL, and units — puts you in control of your weight loss journey and helps you use these powerful medications safely and effectively.

If you have any questions about your specific dosing, please don’t hesitate to reach out to our team at Good Hearts Health.

Additional Resources

• Semaglutide Clinical Trial — New England Journal of Medicine
• Tirzepatide Clinical Trial — New England Journal of Medicine

Medically authored by Dr. Mario Quiros, MD. Diplomate of the American Board of Obesity Medicine. Owner and Operator of Good Hearts Health.

Ready to Start a Physician-Supervised GLP-1 Weight Loss Program?

At Good Hearts Health, Dr. Mario Quiros provides personalized, board-certified concierge weight loss care using FDA-approved Semaglutide and Tirzepatide therapy. If you are considering GLP-1 therapy for weight loss, we offer a free initial consultation to see if our program is right for you.

Book your free consultation with Good Hearts Health today →

One of the most common questions I get from patients starting GLP-1 therapy with Tirzepatide (Mounjaro/Zepbound) or Semaglutide (Ozempic/Wegovy) is: “What type of exercise should I be doing while on GLP-1 medication?”

The short answer: strength and resistance training should be your first priority. Here’s why — and how to structure your routine for the best results.

Understanding the Main Types of Exercise

Before making a recommendation, it helps to understand how the four main categories of exercise work and what each one does for your body.

Aerobic Exercise

Aerobic exercise — also called cardio — includes walking, jogging, hiking, swimming, and cycling. These activities use oxygen to fuel your muscles, elevate your heart rate, and improve breathing over a sustained period.

Benefits of aerobic exercise:

• Improves cardiovascular fitness and heart health
• Lowers blood pressure
• Boosts energy levels
• Burns calories effectively during the activity

Aerobic exercise is generally lower in intensity and longer in duration than anaerobic exercise, and is commonly associated with calorie burning and weight loss.

Anaerobic (Strength & Resistance) Exercise

Anaerobic exercise — including weightlifting, sprinting, HIIT, jumping, and plyometrics — uses energy stored directly in muscles rather than relying on oxygen.

Benefits of anaerobic exercise:

• Increases muscle mass and strength
• Improves insulin sensitivity (something GLP-1 medications like Semaglutide and Tirzepatide also support)
• Decreases risk of osteoporosis
• Prevents cardiac aging
• Lowers cardiovascular risk
• Increases metabolism and resting metabolic rate

Flexibility & Balance Exercise

Flexibility exercises (yoga, stretching) and balance training (tai chi, single-leg work) round out a complete fitness routine. While critical for injury prevention and functional fitness, they are less central to the weight loss goals most GLP-1 patients are working toward.

What Exercise Is Best for Weight Loss and Weight Maintenance?

Exercise is important for weight loss — and even more important for long-term weight maintenance — but the effects of exercise alone on weight loss are modest compared to diet. The most important driver of weight loss is maintaining a caloric deficit over time.

For most patients, a daily deficit of 500–750 calories is the recommended range, producing a healthy, sustainable weight loss of approximately 1.5–2 lbs per week — the target I set for my patients.

This is exactly where GLP-1 medications like Tirzepatide and Semaglutide shine. By suppressing appetite and reducing portion sizes, they make it far easier to consistently run that caloric deficit. Combined with metabolic benefits, your body turns to existing fat reserves for energy — and the weight comes off.

What Exercise Does Dr. Quiros Recommend for Patients on GLP-1 Therapy?

My recommendation: prioritize strength and resistance training. Specifically, I recommend 30–45 minutes per day, 3–4 days per week as a starting baseline.

If you enjoy aerobic exercise, absolutely keep it in your routine — but treat it as secondary to strength training while you are on Semaglutide or Tirzepatide. Here’s why:

1. Optimize Your Body Composition

The caloric deficit produced by GLP-1 medications is more than enough to drive significant weight loss. The question isn’t whether you’ll lose weight — it’s how you lose it.

When you lose weight rapidly without resistance training, your body can break down muscle along with fat. By incorporating strength training, you signal to your body to preserve existing muscle mass and, ideally, build more. This protects your lean mass, increases your fat-burning rate, and leads to a healthier body composition overall.

2. Protect and Increase Your Metabolism

Prolonged caloric deficits can slow your metabolism as your body adapts to using less energy — one of the key reasons patients hit a weight loss plateau. Regular strength and resistance training counteracts this by building muscle, which is metabolically active tissue. More muscle = higher resting metabolic rate = continued fat burning even at rest.

3. Reduce Your Risk of Osteoporosis

Clinical trials for both Semaglutide and Tirzepatide identified bone density loss as a potential side effect. This is especially relevant for women over 65 and postmenopausal patients. Some degree of bone density loss naturally accompanies weight loss — as your skeleton is no longer bearing as much load — but excessive loss can become clinically significant.

Resistance training directly counteracts this by placing mechanical stress on bones, which stimulates bone formation and helps prevent bone loss. Put simply: lifting weights builds stronger bones, not just stronger muscles.

Summary: Aerobic vs. Anaerobic Exercise on GLP-1 Therapy

Frequently Asked Questions

Can I do cardio while on GLP-1 medication?

Yes — cardio is healthy and beneficial. Just make it secondary to strength training, not the other way around.

How soon after starting GLP-1 therapy should I begin exercising?

As soon as you feel ready. Start with lighter resistance and shorter sessions if needed, and build gradually over the first few weeks.

Will I lose muscle on GLP-1 medications?

You can, if you’re not doing resistance training. That’s exactly why it’s the centerpiece of my exercise recommendation for GLP-1 patients.

This post was prepared by:

Dr. Mario I. Quiros
Good Hearts Health — Owner and Founder
Diplomate of the American Board of Obesity Medicine

Further Reading

• Aerobic vs. Anaerobic Exercise: What’s the Difference? — Shape
• Aerobic vs. Anaerobic Exercise — Healthline
• NEJM: Semaglutide Clinical Trial

Ready to Start a Physician-Supervised GLP-1 Weight Loss Program?

At Good Hearts Health, Dr. Mario Quiros provides personalized, board-certified concierge weight loss care using FDA-approved Semaglutide and Tirzepatide therapy. If you are considering GLP-1 therapy for weight loss, we offer a free initial consultation to see if our program is right for you.

Book your free consultation with Good Hearts Health today →